Mercer Global Advisors Inc. ADV Reduces Position in Moderna, Inc. (NASDAQ:MRNA)

Mercer Global Advisors Inc. ADV lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 8.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,078 shares of the company’s stock after selling 2,015 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Moderna were worth $2,724,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna in the 2nd quarter valued at $26,000. Cedar Wealth Management LLC grew its position in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. acquired a new position in Moderna in the first quarter valued at $32,000. Family Firm Inc. purchased a new stake in shares of Moderna in the second quarter valued at about $33,000. Finally, Rise Advisors LLC boosted its stake in shares of Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total value of $1,908,300.00. Following the sale, the director now owns 2,284,015 shares of the company’s stock, valued at $290,572,388.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total value of $1,908,300.00. Following the sale, the director now owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The disclosure for this sale can be found here. In the last three months, insiders sold 93,158 shares of company stock worth $11,167,312. 15.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MRNA. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, September 13th. The Goldman Sachs Group cut their price target on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Barclays decreased their price target on Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a report on Monday, September 16th. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective on the stock in a research note on Wednesday, August 28th. Finally, JPMorgan Chase & Co. cut shares of Moderna from a “neutral” rating to an “underweight” rating and reduced their target price for the stock from $88.00 to $70.00 in a research note on Friday, September 13th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $100.44.

Moderna Stock Performance

NASDAQ MRNA opened at $65.69 on Monday. The business has a 50 day moving average price of $90.07 and a 200 day moving average price of $110.96. The company has a market capitalization of $25.18 billion, a P/E ratio of -4.19 and a beta of 1.67. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same quarter last year, the business posted ($3.62) earnings per share. Sell-side analysts expect that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.